- Home
- BOLT
as of 02-18-2026 2:42pm EST
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
| Founded: | 2015 | Country: | US |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 10.5M | IPO Year: | 2021 |
| Target Price: | $34.00 | AVG Volume (30 days): | 27.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.94 | EPS Growth: | 9.84 |
| 52 Week Low/High: | $0.26 - $7.35 | Next Earning Date: | 02-27-2026 |
| Revenue: | $7,690,000 | Revenue Growth: | -2.36% |
| Revenue Growth (this year): | -31.94% | Revenue Growth (next year): | -54.53% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -61330000.0 | FCF Growth: | N/A |
AI-Powered BOLT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Bolt Biotherapeutics Inc. (BOLT)
President, CEO and CFO
Avg Cost/Share
$4.61
Shares
125
Total Value
$575.88
Owned After
2,313
SEC Form 4
Senior VP, Finance and PAO
Avg Cost/Share
$4.61
Shares
125
Total Value
$575.88
Owned After
1,415
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Quinn William P. | BOLT | President, CEO and CFO | Dec 5, 2025 | Buy | $4.61 | 125 | $575.88 | 2,313 | |
| Nemec Sarah | BOLT | Senior VP, Finance and PAO | Dec 5, 2025 | Buy | $4.61 | 125 | $575.88 | 1,415 |
Compare BOLT vs Leading Stocks
See how BOLT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BOLT Bolt Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.